We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
Read MoreHide Full Article
Aerie Pharmaceuticals, Inc. ( announced that the FDA has approved Rocklatan 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a once-daily, quadruple-action fixed-dose combination of Rhopressa (netarsudil) and Pfizer’s (PFE - Free Report) Xalatan (latanoprost).
The FDA approval was supported by data from two phase III registration studies, MERCURY 1 and MERCURY 2. In these studies, Rocklatan achieved its primary 90-day efficacy endpoint, and positive 12-month safety and efficacy results, demonstrating statistically superior IOP reduction over latanoprost and netarsudil at every measured time point. Aerie’s new drug application (NDA) for Rocklatan 0.02%/0.005% was submitted to the FDA in May 2018.
This is the second FDA approval that the company has received for the treatment of glaucoma within a year of the U.S. launch of Rhopressa. The company plans to launch Rocklatan in the United States in the second quarter of 2019.
Share price of the company decreased 21% in the past year compared with the industry’s decline of 16.6%.
Along with the approval, the company also announced full-year 2019 net revenue and net cash burn guidance. The company expects revenue for 2019 to be $110-$120 million. This guidance includes the combined net revenues of Rhopressa (netarsudil ophthalmic solution) 0.02% and Rocklatan.
As Rocklatan has just received approval, a large portion of the company’s net revenue guidance is expected to be achieved later this year. The company expects to gain meaningful Rocklatan market access for commercial and Medicare Part D plans as the year progresses.
Net cash burn for full-year 2019 is expected to be $130-$140 million. Including the $100-million undrawn credit facility available to the company, total liquidity at the end of 2019 is forecast to be $160-$170 million based on the net cash burn guidance range.
Some top-ranked stocks from the same space are Celgene Corporation and BioDelivery Sciences International, Inc. . While Celgene carries a Zacks Rank #1 (Strong Buy), BioDelivery carries a Zacks Rank#2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene’s earnings per share estimates have increased from $10.34 to $10.73 for 2019 and from $12.28 to $12.76 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.65%.
BioDelivery Sciences’ loss per share estimates have narrowed from 25 cents to 20 cents for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 8.57%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
Aerie Pharmaceuticals, Inc. ( announced that the FDA has approved Rocklatan 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a once-daily, quadruple-action fixed-dose combination of Rhopressa (netarsudil) and Pfizer’s (PFE - Free Report) Xalatan (latanoprost).
The FDA approval was supported by data from two phase III registration studies, MERCURY 1 and MERCURY 2. In these studies, Rocklatan achieved its primary 90-day efficacy endpoint, and positive 12-month safety and efficacy results, demonstrating statistically superior IOP reduction over latanoprost and netarsudil at every measured time point. Aerie’s new drug application (NDA) for Rocklatan 0.02%/0.005% was submitted to the FDA in May 2018.
This is the second FDA approval that the company has received for the treatment of glaucoma within a year of the U.S. launch of Rhopressa. The company plans to launch Rocklatan in the United States in the second quarter of 2019.
Share price of the company decreased 21% in the past year compared with the industry’s decline of 16.6%.
Along with the approval, the company also announced full-year 2019 net revenue and net cash burn guidance. The company expects revenue for 2019 to be $110-$120 million. This guidance includes the combined net revenues of Rhopressa (netarsudil ophthalmic solution) 0.02% and Rocklatan.
As Rocklatan has just received approval, a large portion of the company’s net revenue guidance is expected to be achieved later this year. The company expects to gain meaningful Rocklatan market access for commercial and Medicare Part D plans as the year progresses.
Net cash burn for full-year 2019 is expected to be $130-$140 million. Including the $100-million undrawn credit facility available to the company, total liquidity at the end of 2019 is forecast to be $160-$170 million based on the net cash burn guidance range.
Aerie Pharmaceuticals, Inc. Price
Aerie Pharmaceuticals, Inc. Price | Aerie Pharmaceuticals, Inc. Quote
Zacks Rank and Other Key Picks
Aerie currently carries a Zacks Rank #2 (Buy).
Some top-ranked stocks from the same space are Celgene Corporation and BioDelivery Sciences International, Inc. . While Celgene carries a Zacks Rank #1 (Strong Buy), BioDelivery carries a Zacks Rank#2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene’s earnings per share estimates have increased from $10.34 to $10.73 for 2019 and from $12.28 to $12.76 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.65%.
BioDelivery Sciences’ loss per share estimates have narrowed from 25 cents to 20 cents for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 8.57%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>